MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE. (June 2017) - Pott, C.; Belada, D.; Danesi, N.; Fingerle‐Rowson, G.R.; Gribben, J.; Harbron, C.G.; Hoster, E.; Kahl, B.S.; Kehden, B.; Mundt, K.E.; Nicolas‐Virelizier, E.; Sehn, L.H.; et al.